Search the Newsreel

Tolins Tyres Share Price Outlook: Where It Could Be in 3 Years

Autolus Therapeutics (AUTL) Projected to Release Quarterly Earnings on Tuesday

Mettler Toledo International (MTD) Could Be 4% Overvalued As Strong Earnings Reignite Interest

BioNTech Aktie: BNT327 mit Bristol Myers Squibb

Noida Toll Bridge Q1 FY27: Profit Surge Masks Deeper Structural Concerns

An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.

Reports of a potential megamerger between AstraZeneca and Bristol Myers Squibb have been met with skepticism and a significant stock sell-off on Wall Street. Analysts are perplexed by AstraZeneca's interest, given its strong organic growth, while Bristol Myers faces patent expirations for key products. …

Piper Sandler Maintains Capitol Federal Financial(CFFN.US) With Hold Rating, Raises Target Price to $9.5

Piper Sandler has reiterated its Hold rating on Capitol Federal Financial (CFFN.US) and increased its target price for the stock to $9.5. This indicates a maintained neutral stance with a slightly more optimistic outlook on the stock's future value.

What Toll Brothers (TOL)'s Luxury Community and Design Studio Expansion Means For Shareholders

Toll Brothers has expanded its luxury communities and Design Studio network across multiple U.S. states, offering high-end homes and resort-style amenities. This strategy reinforces its brand as a customizable, lifestyle-focused builder, which is a key part of its investment narrative. While this expansion supports …

Press Release: Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million With Perceptive Advisors

Autolus Therapeutics announced preliminary second quarter 2026 net product revenue and secured a credit facility of up to $250 million with Perceptive Advisors. This financial arrangement is expected to support the company's operational growth and strategic initiatives. The report indicates a positive financial outlook …

Form 144 Mettler-Toledo International Inc. For: 3 August By Investing.com

The article is a Form 144 filing for Mettler-Toledo International Inc. for August 3rd, published by Investing.com. It primarily serves as a placeholder or announcement for the regulatory filing, with minimal actual content beyond the title and date. The piece also includes stock performance …

Mettler-Toledo appoints Natalia Shuman to board of directors

Mettler-Toledo International Inc. has announced the appointment of Natalia Shuman to its board of directors, effective immediately. Shuman currently serves as president and CEO of MISTRAS Group and has extensive leadership experience in global organizations providing testing, inspection, and certification services. Her background aligns …

Jim Cramer Senses a 'Fake Out' in Rumored AstraZeneca, Bristol Myers Squibb $400 Billion Mega-Merger

Jim Cramer expressed skepticism regarding the rumored $400 billion mega-merger between AstraZeneca and Bristol Myers Squibb, calling it a potential "fake out" and suggesting BMY needs assistance. The Financial Times reported ongoing discussions, which could lead to a cash and stock deal, combining AstraZeneca's …

Autolus Sets Aug. 11 Webcast for Q2 Results and Business Update

Autolus Therapeutics (Nasdaq: AUTL) will release its second-quarter 2026 financial results and operational highlights before the U.S. market opens on Tuesday, August 11, 2026. The company will also host a conference call and webcast at 8:30 AM EDT / 1:30 PM BST to discuss …

Autolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026

Autolus Therapeutics plc (Nasdaq: AUTL) announced it will release its second quarter 2026 financial results and operational highlights before the open of U.S. markets on Tuesday, August 11, 2026. Management will host a conference call and webcast at 8:30 am EDT / 1:30 pm …

Mettler-Toledo International, Inc. Stock 12‑Month Price Target Raised to $1495.8, Implies 6% Upside

Mettler-Toledo International, Inc.'s average stock price target has been raised to $1495.8 from $1478.3, according to estimates from 10 analysts. This updated target suggests a potential 6% upside based on the July 31 closing price. The consensus rating among 15 analysts remains a "Buy," …

CFFN Maintained by Piper Sandler -- Price Target Raised to $9.50

Piper Sandler has maintained a Neutral rating on Capitol Federal Financial (CFFN) but increased its price target to $9.50 from $8.50. The company, a bank holding company operating in Kansas, currently has a P/E (TTM) of 13.88 and a GF Score™ of 30/100, indicating …

What Capitol Federal Financial (CFFN)'s Strong Q3 Results and Completed Buyback Mean For Shareholders

Capitol Federal Financial (CFFN) reported strong Q3 2026 results with increased net interest income and net income, along with the completion of a significant share buyback program and a reaffirmed quarterly dividend. These results highlight the company's focus on capital return and operational efficiency. …

Autolus raises sales guidance, secures $75M credit facility

Autolus Therapeutics plc announced preliminary Q2 2026 net product revenue of approximately $45 million for AUCATZYL and raised its full-year sales guidance to $140-$150 million. The company also secured a credit facility of up to $250 million with Perceptive Advisors, receiving an initial $75 …

Barclays Raises Mettler-Toledo International (NYSE:MTD) Price Target to $1,575.00

Barclays has increased its price target for Mettler-Toledo International (NYSE:MTD) to $1,575.00 from $1,300.00, maintaining an "overweight" rating. This new target suggests an 11.03% potential upside from the stock's previous close. The company recently reported strong quarterly earnings, surpassing analyst expectations with $11.46 EPS …

Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea

The article argues that a potential merger between AstraZeneca and Bristol Myers Squibb, valued at nearly $400 billion, would be a disaster. It highlights severe regulatory concerns due to significant portfolio overlaps, potential pipeline disruptions, and massive job losses as key reasons against such …

Noida Toll Bridge Company: ₹5.33 ਕਰੋੜ ਦਾ ਮੁਨਾਫਾ, ਪਰ ₹100 ਕਰੋੜ ਦੀ NOIDA ਮੰਗ ਦਾ ਸਾਹਮਣਾ

Autolus Secures $250 Million Notes Facility From Perceptive, Issues Warrants and Registration Rights

Autolus Therapeutics has secured a senior secured notes facility worth up to $250 million from Perceptive, with an initial draw of $75 million. The agreement includes the issuance of warrants for up to 3.5 million ADSs to Perceptive and grants registration rights for their …

Toll Brothers sued: Michigan woman claims luxury housing project could block access to her land, harm envi

A Michigan woman, Susan Miller, is suing luxury homebuilder Toll Brothers over a proposed 107-home development, alleging it will block access to her 19-acre property and cause environmental damage. The lawsuit focuses on a disputed easement and the potential impact of two private wastewater …

Wells Fargo Adjusts PT on Mettler-Toledo International to $1,450 From $1,225, Keeps Equalweight Rating

Wells Fargo has increased its price target for Mettler-Toledo International (MTD) to $1,450 from $1,225, while maintaining an Equalweight rating on the stock. This adjustment comes amidst recent analyst actions, with other firms like Morgan Stanley, Stifel, and Goldman Sachs also updating their price …

AstraZeneca tops pharma growth rankings while Bristol Myers trails amid merger talks (XLV:NYSEARCA)

AstraZeneca leads pharmaceutical growth rankings with an 'A' Growth Grade, while Bristol Myers Squibb lags with a 'D' grade. This comes amidst reports that the two companies are exploring a merger, which would create one of the world's largest pharmaceutical firms. A merger would …

AstraZeneca falls to third-largest UK company amid US merger talks

AstraZeneca's market value dropped by over £17bn after reports emerged of its discussions to acquire US rival Bristol Myers Squibb for nearly $400bn, causing it to lose its position as the second-largest UK company to Shell. Analysts and shareholders have expressed skepticism about the …

Analysts baffled by AstraZeneca's interest in Bristol Myers Squibb

Analysts are perplexed by AstraZeneca's reported interest in acquiring Bristol-Myers Squibb, especially given AstraZeneca's strong growth and innovation. Both Jefferies and UBS, while maintaining 'buy' ratings on AstraZeneca, raised concerns about the strategic fit, potential pipeline overlap, looming patent expiries for Bristol-Myers Squibb's key …

Capitol Federal Financial (NASDAQ:CFFN) Reaches New 1-Year High - Here's What Happened

The $400 Billion Reason Bristol-Myers Squibb (BMY) Stock Is Up Today

Dimensional Fund Advisors LP Purchases 263,238 Shares of Capitol Federal Financial $CFFN

Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up - Still a Buy?

Bristol Myers Squibb (BMY) In Early Merger Talks With AstraZeneca

Noida Toll Bridge Q1FY27 net profit rises 28.7% as court stays fee demand

AstraZeneca slides after reports of Bristol Myers merger talks leave analysts 'perplexed'

AstraZeneca's stock fell sharply after reports emerged of potential merger talks with Bristol Myers Squibb, a deal that could create a $400 billion pharmaceutical giant. Analysts expressed bewilderment over the strategic rationale, given AstraZeneca's strong growth and pipeline, while Bristol Myers faces upcoming patent …

Capitol Federal Financial (CFFN) Following Q3 Results And Buybacks, Is The Stock Already Priced In?

Capitol Federal Financial (CFFN) has garnered renewed interest following its Q3 2026 results, cash dividend affirmation, and share repurchase program. While the stock's Price-to-Earnings ratio of 13.3x suggests it's slightly overvalued compared to its US Banks peers and its estimated fair multiple of 11.9x, …

AstraZeneca, Bristol Myers Squibb Reportedly in Talks for $400 Billion Merger

AstraZeneca and Bristol Myers Squibb are reportedly in discussions for a merger that could create a pharmaceutical giant valued at approximately $400 billion. The talks have been ongoing for several months and, if successful, would make AstraZeneca the world’s fourth-largest drugmaker by market capitalization. …